EUVIMEDObjevte EUVIMED
Crossref

Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1

Zheng Zeng, Caiji Lin, Meng-Chun Zhang, Pathum Kossinna, Pengfei Wang, Danli Cao, Jiaxing Wang, Mengzhi Xu, Xiaoyu Wang, Qing Li, Xiaohui Xu, Hao Yang and 11 more

Phytotherapy Research · 2023

DOI: 10.1002/ptr.7942 ↗

At a glance

Journal article in Phytotherapy Research, 2023. Written by Zheng Zeng and 22 co-authors. Institution: Genomics Research Center, Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, State-Province Key Laboratory of Biomedicin…. Major MEDLINE topics: Thrombospondin 1, Ovarian Neoplasms. Cited 15 times so far (Crossref); 46 references. Funded by: China Scholarship Council, College of Pharmacy, Harbin Medical University, Excellent Young Talents Funding, Heilongjiang Postdoctoral Financial Assistance.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Epithelial ovarian cancer (EOC) is the most common and fatal subtype of ovarian malignancies, with no effective therapeutics available. Our previous studies have demonstrated extraordinary suppressive efficacy of enterolactone (ENL) on EOC. A chemotherapeutic agent, trabectedin (Trabe), is shown to be effective on ovarian cancer, especially when combined with other therapeutics, such as pegylated liposomal doxorubicin or oxaliplatin. Thrombospondin 1 (THBS1), a kind of matrix glycoprotein, plays important roles against cancer development through inhibiting angiogenesis but whether it is involved in the suppression of EOC by ENL or Trabe remains unknown. To test combined suppressive effects of ENL and Trabe on EOC and possible involvement of THBS1 in the anticancer activities of ENL and Trabe. The EOC cell line ES‐2 was transfected with overexpressed THBS1 by lentivirus vector. We employed tube formation assay to evaluate the anti‐angiogenesis activity of ENL and of its combined use with Trabe after THBS1 overexpression and established drug intervention and xenograft nude mouse cancer models to assess the in vivo effects of the hypothesized synergistic suppression between the agents and the involvement of THBS1. Mouse fecal samples were collected for 16S rDNA sequencing and microbiota analysis. We detected strong inhibitory activities of ENL and Trabe against the proliferation and migration of cancer cells and observed synergistic effects between ENL and Trabe in suppressing EOC. ENL and Trabe, given either separately or in combination, could suppress the tube formation capability of human microvascular endothelial cells, and this inhibitory effect became even stronger with THBS1 overexpression. In the ENL plus Trabe combination group, the expression of tissue inhibitor of metalloproteinases 3 and cluster of differentiation 36 was both upregulated, whereas matrix metalloproteinase 9, vascular endothelial growth factor, and cluster of differentiation 47 were all decreased. With the overexpression of THBS1, the results became even more pronounced. In animal experiments, combined use of ENL and Trabe showed superior inhibitory effects to either single agent and significantly suppressed tumor growth, and the overexpression of THBS1 further enhanced the anti‐cancer activities of the drug combination group. ENL and Trabe synergistically suppress EOC and THBS1 could remarkably facilitate the synergistic anticancer effects of ENL and Trabe.

Subjects

MeSH terms (MEDLINE)

Thrombospondin 1Ovarian NeoplasmsAnimalsMiceHumansFemaleCarcinoma, Ovarian EpithelialTrabectedinVascular Endothelial Growth Factor AEndothelial CellsCell Line, TumorCell Proliferation4-ButyrolactoneLignans

Author keywords

THBS1enterolactoneepithelial ovarian cancersynergistic anti-cancer effectstrabectedin

Substances

TrabectedinThrombospondin 1Vascular Endothelial Growth Factor A2,3-bis(3'-hydroxybenzyl)butyrolactone4-ButyrolactoneLignans

Authors and institutions

  • Genomics Research Center, Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, State-Province Key Laboratory of Biomedicine-Pharmaceutics of China, College of Pharmacy, Harbin Medical Universi…
  • Harbin Medical University-University of Calgary Cumming School of Medicine Centre for Infection and Genomics, Harbin Medical University, Harbin, China.
  • Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada.
  • School of Biomedical Science, The University of Hong Kong, Hong Kong.
  • School of Basic Medicine, Harbin Medical University, Harbin, China.
  • Department of Pathology, Harbin Chest Hospital, Harbin, China.

ORCID profiles: Shu-Lin Liu, Huidi Liu

Funding

  • China Scholarship Council
  • College of Pharmacy, Harbin Medical University, Excellent Young Talents Funding
  • Heilongjiang Postdoctoral Financial Assistance
  • HMU Marshal Initiative Funding
  • Merit-based Funding for Returned Oversea Students in Heilongjiang Province
  • National Natural Science Foundation of China

Cite

APA

Zeng, Z., Lin, C., Zhang, M. C., Kossinna, P., Wang, P., Cao, D., Wang, J., Xu, M., Wang, X., Li, Q., Xu, X., Yang, H., Zhu, S., Liu, G. R., Xie, K., Yang, J., Luo, Y., Wang, Y., Zhang, X. H., …, & Liu, H. (2023). Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1. Phytotherapy Research. https://doi.org/10.1002/ptr.7942

Vancouver

Zeng Z, Lin C, Zhang MC, Kossinna P, Wang P, Cao D, et al. Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1. Phytotherapy Research. 2023. doi:10.1002/ptr.7942

BibTeX
@article{Zeng2023,
  author = {Zeng, Zheng and Lin, Caiji and Zhang, Meng-Chun and Kossinna, Pathum and Wang, Pengfei and Cao, Danli and Wang, Jiaxing and Xu, Mengzhi and Wang, Xiaoyu and Li, Qing and Xu, Xiaohui and Yang, Hao and Zhu, Songling and Liu, Gui-Rong and Xie, Kaihong and Yang, Jiaming and Luo, Yao and Wang, Yao and Zhang, Xing-Hua and Lin, Jingwen and Chen, Hang and Liu, Shu-Lin and Liu, Huidi},
  title = {Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1},
  journal = {Phytotherapy Research},
  year = {2023},
  doi = {10.1002/ptr.7942}
}
Start for free →